Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation

References

• Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics. 2020;52(11):549–557. doi:10.1152/physiolgenomics.00089.2020
   PubMed Web of Science ®Google Scholar
• Singh AK, Gillies CL, Singh R, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis. Diabetes Obes Metab. 2020;22(10):1915–1924. doi:10.1111/dom.14124
   PubMed Web of Science ®Google Scholar
• Gustine JN, Jones D. Immunopathology of hyperinflammation in COVID-19. Am J Pathol. 2021;191(1):4–17. doi:10.1016/j.ajpath.2020.08.009
   PubMed Web of Science ®Google Scholar
• Panigrahy D, Gilligan MM, Huang S, et al. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? Cancer Metastasis Rev. 2020;39(2):337–340. doi:10.1007/s10555-020-09889-4
   PubMed Web of Science ®Google Scholar
• Zabetakis I, Lordan R, Norton C, Tsoupras A. COVID-19: the inflammation link and the role of nutrition in potential mitigation. Nutrients. 2020;12:5. doi:10.3390/nu12051466
   Web of Science ®Google Scholar
• Shakoor H, Feehan J, Al Dhaheri AS, et al. Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: could they help against COVID-19? Maturitas. 2021;143:1–9. doi:10.1016/j.maturitas.2020.08.003
   PubMed Web of Science ®Google Scholar
• Hunter P. The inflammation theory of disease. The growing realization that chronic inflammation is crucial in many diseases opens new avenues for treatment. EMBO Rep. 2012;13(11):968–970. doi:10.1038/embor.2012.142
   PubMed Web of Science ®Google Scholar
• Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:586. doi:10.3389/fimmu.2018.00586
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev. 2007;65(12 Pt 2):S140–S146. doi:10.1111/j.1753-4887.2007.tb00352.x
   PubMed Web of Science ®Google Scholar
• Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34:2. doi:10.23812/CONTI-E
   Web of Science ®Google Scholar
• Amiri-Dashatan N, Koushki M, Ghorbani F, Naderi N. Increased inflammatory markers correlate with liver damage and predict severe COVID-19: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2020;13(4):282–291.
   PubMedGoogle Scholar
• Renu K, Prasanna PL, Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review. Life Sci. 2020;255:117839. doi:10.1016/j.lfs.2020.117839
   PubMed Web of Science ®Google Scholar
• Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun. 2002;16(6):622–653. doi:10.1016/s0889-1591(02)00021-1
   PubMed Web of Science ®Google Scholar
• Coronavirus Disease (COVID-19) situation reports. Avaiable from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed January 28, 2021.
   Google Scholar
• Wang F, Kream RM, Stefano GB. Long-term respiratory and neurological sequelae of COVID-19. Med Sci Monit. 2020;26:e928996. doi:10.12659/MSM.928996
   PubMed Web of Science ®Google Scholar
• Verkhratsky A, Li Q, Melino S, Melino G, Shi Y. Can COVID-19 pandemic boost the epidemic of neurodegenerative diseases? Biol Direct. 2020;15(1):28. doi:10.1186/s13062-020-00282-3
   PubMed Web of Science ®Google Scholar
• McDonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. 2021;320(2):L257–L265. doi:10.1152/ajplung.00238.2020
   PubMed Web of Science ®Google Scholar
• O’Sullivan O. Long-term sequelae following previous coronavirus epidemics. Clin Med. 2021;21(1):e68–e70. doi:10.7861/clinmed.2020-0204
   PubMed Web of Science ®Google Scholar
• Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20:2. doi:10.1007/s11906-018-0812-z
   PubMed Web of Science ®Google Scholar
• Leijte WT, Wagemaker NMM, van Kraaij TDA, et al. Mortality and re-admission after hospitalization with COVID-19. Ned Tijdschr Geneeskd. 2020;164:D5423.
   PubMedGoogle Scholar
• NIH launches new initiative to study. “Long COVID.” National Institutes of Health (NIH); February 23, 2021. Available from: https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid. Accessed March 30, 2021.
   Google Scholar
• Li S, Zhang Y, Guan Z, et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct Target Ther. 2020;5(1):235. doi:10.1038/s41392-020-00334-0
   PubMed Web of Science ®Google Scholar
• Pum A, Ennemoser M, Adage T, Kungl AJ. Cytokines and chemokines in SARS-CoV-2 infections—therapeutic strategies targeting cytokine storm. Biomolecules. 2021;11:1. doi:10.3390/biom11010091
   Web of Science ®Google Scholar
• Choudhary S, Sharma K, Silakari O. The interplay between inflammatory pathways and COVID-19: a critical review on pathogenesis and therapeutic options. Microb Pathog. 2021;150:104673. doi:10.1016/j.micpath.2020.104673
   PubMed Web of Science ®Google Scholar
• Chen Y-M, Zheng Y, Yu Y, et al. Blood molecular markers associated with COVID-19 immunopathology and multi-organ damage. EMBO J. 2020;39(24):e105896. doi:10.15252/embj.2020105896
   PubMed Web of Science ®Google Scholar
• Mak JC, Chan-Yeung MM, Ho SP, et al. Elevated plasma TGF-beta1 levels in patients with chronic obstructive pulmonary disease. Respir Med. 2009;103:1083–1089. doi:10.1016/j.rmed.2009.01.005
   PubMed Web of Science ®Google Scholar
• Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9:761–770. doi:10.1080/22221751.2020.1747363
   PubMed Web of Science ®Google Scholar
• Woods PS, Tazi MF, Chesarino NM, Amer AO, Davis IC. TGF-beta-induced IL-6 prevents development of acute lung injury in influenza A virus-infected F508del CFTR-heterozygous mice. Am J Physiol Lung Cell Mol Physiol. 2015;308:L1136–L1144. doi:10.1152/ajplung.00078.2015
   PubMed Web of Science ®Google Scholar
• Mu E, Ding R, An X, Li X, Chen S, Ma X. Heparin attenuates lipopolysaccharide-induced acute lung injury by inhibiting nitric oxide synthase and TGF-beta/Smad signaling pathway. Thromb Res. 2012;129:479–485. doi:10.1016/j.thromres.2011.10.003
   PubMed Web of Science ®Google Scholar
• Pittet JF, Griffiths MJ, Geiser T, et al. TGF-beta is a critical mediator of acute lung injury. J Clin Invest. 2001;107:1537–1544. doi:10.1172/JCI11963
   PubMed Web of Science ®Google Scholar
• Chen W. A potential treatment of COVID-19 with TGF-beta blockade. Int J Biol Sci. 2020;16:1954–1955. doi:10.7150/ijbs.46891
   PubMed Web of Science ®Google Scholar
• Hu X, Huang X. Alleviation of inflammatory response of pulmonary fibrosis in acute respiratory distress syndrome by puerarin via Transforming Growth Factor (TGF-beta1). Med Sci Monit. 2019;25:6523–6531. doi:10.12659/MSM.915570
   PubMed Web of Science ®Google Scholar
• Li SW, Wang CY, Jou YJ, et al. SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF-beta1 via ROS/p38 MAPK/STAT3 pathway. Sci Rep. 2016;6:25754. doi:10.1038/srep25754
   PubMed Web of Science ®Google Scholar
• Wang CY, Lu CY, Li SW, et al. SARS coronavirus papain-like protease up-regulates the collagen expression through non-Samd TGF-beta1 signaling. Virus Res. 2017;235:58–66. doi:10.1016/j.virusres.2017.04.008
   PubMed Web of Science ®Google Scholar
• Mendelson M, Nel J, Blumberg L, et al. Long-COVID: an evolving problem with an extensive impact. S Afr Med J. 2020;111(1):10–12. doi:10.7196/SAMJ.2020.v111i11.15433
   PubMed Web of Science ®Google Scholar
• Ali A, Katz DL. Disease prevention and health promotion. Am J Prev Med. 2015;49(50 3):S230–S240. doi:10.1016/j.amepre.2015.07.019
   PubMedGoogle Scholar
• Morgan N, Irwin MR, Chung M, Wang C, Bacurau RFP. The effects of mind-body therapies on the immune system: meta-analysis. PLoS One. 2014;9(7):e100903. doi:10.1371/journal.pone.0100903
   PubMed Web of Science ®Google Scholar
• Jolliffe DA, Camargo CA, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol. 2021;9(5):276–292. doi:10.1016/S2213-8587(21)00051-6
   PubMed Web of Science ®Google Scholar
• Zhang R, Wang X, Ni L, et al. COVID-19: melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583. doi:10.1016/j.lfs.2020.117583
   PubMed Web of Science ®Google Scholar
• Zerr P, Vollath S, Palumbo-Zerr K, et al. Vitamin D receptor regulates TGF-beta signalling in systemic sclerosis. Ann Rheum Dis. 2015;74:e20. doi:10.1136/annrheumdis-2013-204378
   PubMed Web of Science ®Google Scholar
• Isik S, Ozuguz U, Tutuncu YA, et al. Serum transforming growth factor-beta levels in patients with vitamin D deficiency. Eur J Intern Med. 2012;23:93–97. doi:10.1016/j.ejim.2011.09.017
   PubMed Web of Science ®Google Scholar
• Kapepula PM, Kabengele JK, Kingombe M, et al. Artemisia Spp. derivatives for COVID-19 treatment: anecdotal use, political hype, treatment potential, challenges, and road map to randomized clinical trials. Am J Trop Med Hyg. 2020;103:960–964. doi:10.4269/ajtmh.20-0820
   PubMed Web of Science ®Google Scholar
• Uckun FM, Saund S, Windlass H, Trieu V. Repurposing anti-malaria phytomedicine artemisinin as a COVID-19 drug. Front Pharmacol. 2021;12:649532. doi:10.3389/fphar.2021.649532
   PubMed Web of Science ®Google Scholar
• Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020;203:105751. doi:10.1016/j.jsbmb.2020.105751
   PubMed Web of Science ®Google Scholar
• Ling SF, Broad E, Murphy R, et al. High-dose cholecalciferol booster therapy is associated with a reduced risk of mortality in patients with COVID-19: a Cross-Sectional Multi-Centre Observational Study. Nutrients. 2020;12:12. doi:10.3390/nu12123799
   Web of Science ®Google Scholar
• Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020;12(4). doi:10.3390/nu12040988
   Web of Science ®Google Scholar
• Feitosa EL, Júnior FTDSS, Nery Neto JADO, et al. COVID-19: rational discovery of the therapeutic potential of melatonin as a SARS-CoV-2 main protease inhibitor. Int J Med Sci. 2020;17(14):2133–2146. doi:10.7150/ijms.48053
   PubMed Web of Science ®Google Scholar
• Cahn BR, Goodman MS, Peterson CT, Maturi R, Mills PJ. Yoga, meditation and mind-body health: increased BDNF, cortisol awakening response, and altered inflammatory marker expression after a 3-month yoga and meditation retreat. Front Hum Neurosci. 2017;11:315. doi:10.3389/fnhum.2017.00315
   PubMed Web of Science ®Google Scholar
• Bushell WC, Theise ND. Toward a unified field of study: longevity, regeneration, and protection of health through meditation and related practices. Ann N Y Acad Sci. 2009;1172:5–19. doi:10.1111/j.1749-6632.2009.04959.x
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-9
   PubMed Web of Science ®Google Scholar
• Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972–1988. doi:10.1080/21645515.2017.1316909
   PubMed Web of Science ®Google Scholar
• Bushell W, Castle R, Williams MA, et al. Meditation and yoga practices as potential adjunctive treatment of SARS-CoV-2 infection and COVID-19: a brief overview of key subjects. J Altern Complement Med. 2020;26(7):547–556. doi:10.1089/acm.2020.0177
   PubMed Web of Science ®Google Scholar
• Aiswarya D, Arumugam V, Dineshkumar T, et al. Use of remdesivir in patients with COVID-19 on hemodialysis: a Study of Safety and Tolerance. Kidney Int Rep. 2021;6(3):586–593. doi:10.1016/j.ekir.2020.12.003
   PubMed Web of Science ®Google Scholar
• Akbari H, Tabrizi R, Lankarani KB, et al. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Life Sci. 2020;258:118167. doi:10.1016/j.lfs.2020.118167
   PubMed Web of Science ®Google Scholar
• Alamdari NM, Mahdavi R, Roshanravan N, et al. Placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women. Horm Metab Res. 2015;47(07):504–508. doi:10.1055/s-0034-1384587
   PubMedGoogle Scholar
• Bartels LE, Jørgensen SP, Bendix M, et al. 25-hydroxy vitamin D3 modulates dendritic cell phenotype and function in crohn’s disease. Inflammopharmacology. 2013;21(2):177–186. doi:10.1007/s10787-012-0168-y
   PubMed Web of Science ®Google Scholar
• Bower JE, Crosswell AD, Stanton AL, et al. Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer. 2015;121(8):1231–1240. doi:10.1002/cncr.29194
   PubMed Web of Science ®Google Scholar
• Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress, and immune parameters in breast and prostate cancer outpatients. Psychosom Med. 2003;65(4):571–581. doi:10.1097/01.psy.0000074003.35911.41
   PubMed Web of Science ®Google Scholar
• Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology. 2004;29(4):448–474. doi:10.1016/s0306-4530(03)00054-4
   PubMed Web of Science ®Google Scholar
• Carlson LE, Speca M, Faris P, Patel KD. One year pre-post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. Brain Behav Immun. 2007;21(8):1038–1049. doi:10.1016/j.bbi.2007.04.002
   PubMed Web of Science ®Google Scholar
• Celinski K, Konturek PC, Slomka M, et al. Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease–14 months follow up. J Physiol Pharmacol. 2014;65(1):75–82.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi:10.1172/JCI137244
   PubMed Web of Science ®Google Scholar
• Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E005. doi:10.3760/cma.j.issn.1001-0939.2020.0005
   PubMedGoogle Scholar
• Cichoz-Lach H, Celinski K, Konturek PC, Konturek SJ, Slomka M. The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis. J Physiol Pharmacol. 2010;61(5):577–580.
   PubMed Web of Science ®Google Scholar
• Epel ES, Puterman E, Lin J, et al. Meditation and vacation effects have an impact on disease-associated molecular phenotypes. Transl Psychiatry. 2016;6(8):e880. doi:10.1038/tp.2016.164
   PubMedGoogle Scholar
• Gonzalez-Garcia M, Ferrer MJ, Borras X, et al. Effectiveness of mindfulness-based cognitive therapy on the quality of life, emotional status, and CD4 cell count of patients aging with HIV infection. AIDS Behav. 2014;18(4):676–685. doi:10.1007/s10461-013-0612-z
   PubMed Web of Science ®Google Scholar
• Javanmard SH, Heshmat-Ghahdarijani K, Mirmohammad-Sadeghi M, Sonbolestan SA, Ziayi A. The effect of melatonin on endothelial dysfunction in patient undergoing coronary artery bypass grafting surgery. Adv Biomed Res. 2016;5:174. doi:10.4103/2277-9175.194801
   PubMedGoogle Scholar
• Lengacher Ca, Kip KE, Post-White J, et al. Lymphocyte recovery after breast cancer treatment and mindfulness-based stress reduction (MBSR) therapy. Biol Res Nurs. 2013;15(1):37–47. doi:10.1177/1099800411419245
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa248
   Web of Science ®Google Scholar
• Rausch-Fan X, Leutmezer F, Willheim M, et al. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol. 2002;128(1):33–41. doi:10.1159/000058001
   PubMed Web of Science ®Google Scholar
• Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38(1):191–196. doi:10.1016/j.clnu.2017.12.004
   PubMed Web of Science ®Google Scholar
• Rosenkranz MA, Lutz A, Perlman DM, et al. Reduced stress and inflammatory responsiveness in experienced meditators compared to a matched healthy control group. Psychoneuroendocrinology. 2016;68:117–125. doi:10.1016/j.psyneuen.2016.02.013
   PubMed Web of Science ®Google Scholar
• Shete SU, Verma A, Kulkarni DD, Bhogal RS. Effect of yoga training on inflammatory cytokines and C-reactive protein in employees of small-scale industries. J Educ Health Promot. 2017;6:76. doi:10.4103/jehp.jehp_65_17
   PubMedGoogle Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–997. doi:10.1016/S0140-6736(08)60453-5
   PubMed Web of Science ®Google Scholar
• Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221(11):1762–1769. doi:10.1093/infdis/jiaa150
   PubMed Web of Science ®Google Scholar
• Witek-Janusek L, Albuquerque K, Chroniak KR, Chroniak C, Durazo-Arvizu R, Mathews HL. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. Brain Behav Immun. 2008;22(6):969–981. doi:10.1016/j.bbi.2008.01.012
   PubMed Web of Science ®Google Scholar
• Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760. doi:10.1080/22221751.2020.1746200
   PubMed Web of Science ®Google Scholar
• Ramezani M, Simani L, Karimialavijeh E, Rezaei O, Hajiesmaeili M, Pakdaman H. The role of anxiety and cortisol in outcomes of patients with covid-19. Basic Clin Neurosci. 2020;11(2):179–184. doi:10.32598/bcn.11.covid19.1168.2
   PubMed Web of Science ®Google Scholar
• Magro G. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides tocilizumab? SGP130Fc. Cytokine X. 2020;2(2):100029. doi:10.1016/j.cytox.2020.100029
   PubMedGoogle Scholar
• Wasserstein RL, Lazar NA. The ASA statement on p-values: context, process, and purpose. Am Stat. 2016;70:2129–2133. doi:10.1080/00031305.2016.1154108
   Web of Science ®Google Scholar
• Faraone SV. Interpreting estimates of treatment effects. P T. 2008;33(12):700–711.
   PubMedGoogle Scholar
• Mihara M 1, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731–1740. doi:10.1016/j.intimp.2005.05.010
   PubMed Web of Science ®Google Scholar
• Lin Y, Wu F, Xie Z, et al. Clinical study of artesunate in the treatment of coronavirus disease 2019. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32:417–420. doi:10.3760/cma.j.cn121430-20200312-00412
   PubMedGoogle Scholar